By Joe Gorelick, MSN, FNP-C This is very exciting information that may allow us to make early interventions that may modify to course of diseases. Analysis of tape strip samples from two-month babies predicted the likelihood of developing food allergies by age of two,...
As many as seven in 10 people with eczema report that the disease has had a negative impact on their mental health in the past year. About two-thirds of adults with eczema had anxiety scores that were “borderline abnormal” or “abnormal,” and...
Galderma has submitted Biologics License Applications (BLAs) for nemolizumab for the treatment of prurigo nodularis (PN) and for moderate to severe atopic dermatitis (AD) in adolescents and adults. Nemolizumab is a first-in-class investigational monoclonal antibody...
Dermavant Sciences has submitted a Supplemental New Drug Application (sNDA) to the U.S. FDA for Vtama® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older. VTAMA cream, 1% is currently FDA-approved...
What’s the difference between primary and secondary failure of a biologic? And why does it matter? Exploring an actual patient case, faculty from the DEF Biologic and Small Molecule NP/PA CME Bootcamp—April Armstrong, MD, MPH; David E. Cohen, MD, MPH; Kara Gooding,...
FDA has approved the expanded label for LEO Pharma’s Adbry® (tralokinumab-ldrm) to include pediatric patients aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those...